Last update Jan. 29, 2017

C22H19NO4

Compatible

Safe substance and/or breastfeeding is the best option.

A laxative which acts as stimulant in the intestine.

A low oral bioavailability due to minimal intestinal absorption that renders the plasma levels being very low would explain the non passage to breast milk observed (undetectable levels: Friedrich 2011).

On prevention or treating constipation, it is essential a balanced and rich-in-fiber diet along with a lot of fluids and physical exercise.

Alternatives

  • Docusate (Safe substance and/or breastfeeding is the best option.)
  • Lactulose (Safe substance and/or breastfeeding is the best option.)
  • Liquid Paraffin (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

C22H19NO4 is Bisacodyl in Molecular formula.

Is written in other languages:

Group

C22H19NO4 belongs to this group or family:

Tradenames

Main tradenames from several countries containing C22H19NO4 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. < 5 %
Molecular weight 361 daltons
Tmax 4 - 10 hours
T½ 16.5 hours
Theoretical Dose 0 mg/Kg/d
Relative Dose 0 %
Ped.Relat.Dose 0 %

References

  1. Gharehbaghi K, Gharehbaghi DR, Wierrani F, Sliutz G. [Treatment of Chronic Functional Constipation during Pregnancy and Lactation]. Z Geburtshilfe Neonatol. 2016 Abstract
  2. Müller-Lissner S. Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments. Expert Opin Drug Metab Toxicol. 2013 Abstract
  3. AEMPS. Bisacodilo. Ficha técnica. 2012 Full text (in our servers)
  4. Friedrich C, Richter E, Trommeshauser D, de Kruif S, van Iersel T, Mandel K, Gessner U. Absence of excretion of the active moiety of bisacodyl and sodium picosulfate into human breast milk: an open-label, parallel-group, multiple-dose study in healthy lactating women. Drug Metab Pharmacokinet. 2011 Abstract Full text (link to original source) Full text (in our servers)
  5. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul;131(1):283-311. Review. Abstract Full text (link to original source) Full text (in our servers)
  6. Müller-Lissner S. [Side effects of laxatives]. Z Gastroenterol. 1992 Abstract
  7. Vorherr H. Drug excretion in breast milk. Postgrad Med. 1974 Oct;56(4):97-104. Review. No abstract available. Abstract

Total visits

2,636

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM